Prateek Prasanna1, Raymond Huang2, Andrew Rose1, Gagandeep Singh1, Anant Madabhushi1, and Pallavi Tiwari1
1Case Western Reserve University, Cleveland, OH, United States, 2Brigham and Women's Hospital, Boston, MA, United States
Pseudoprogression is an early-delayed inflammatory response to chemoradiotherapy typically appearing up to 3 months post-treatment in brain tumors. On routine MRI, pseudoprogression closely mimics the appearance of true progression, thereby making their visual identification challenging. Early diagnosis of pseudoprogression has implications in management of treatment effects and subsequently survival. We present initial results of using a newly developed radiomic descriptor, CoLlAGE, in distinguishing the two pathologies. We report that CoLlAGe measurements when captured from the necrotic region as opposed to just the enhancing region on MRI can reliably distinguish psuedo-progression from true progression with 100% accuracy (n=17)
